The mRNA Writing On The Wall, GSK Expands CureVac Alliance Into Next-Gen COVID-19 Vaccines
Includes 100m Dose Boost To CureVac's COVID-19 Manufacturing
After major setbacks to its existing COVID-19 vaccine platform, GSK is expanding its presence in mRNA, which increasingly looks to be the future.
You may also be interested in...
Sanofi is beefing up its investment in mRNA vaccine technology with a €400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.
The company is focusing on new technologies, including mRNA, and expects the vaccines business to deliver a high single-digit sales CAGR over the next five years.
The pandemic has reignited interest and investment in vaccines across a wide array of disease areas by big pharma and venture investors, a panel of BIO experts said.